Online supplementary table: Most commonly used biological agents in paediatric patients

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Generic name (Abbreviation) | Mechanism of action | Route | Standard dosage | Approval for paediatric patients | |
| EMA | FDA |
| Etanercept (ETA) | Fusion protein TNF receptor linked to FcIgG1 | SC | * 0.4 mg/kg twice weekly * Maximum 50 mg/dose | Yes | Yes |
| Infliximab (INF) | Chimeric monoclonal  anti-TNF antibody  (mouse-human) | IV | * 5 mg/kg, induction phase at 0, 2, 6 weeks, then every 8 weeks | Yes | Yes |
| Adalimumab  (ADA) | Human monoclonal  anti-TNF antibody | SC | * weight <30 kg: 20 mg every 2 weeks * weight >30 kg: 40 mg every 2 weeks | Yes | Yes |
| Anakinra  (ANK) | IL-1 receptor antagonist | SC | * 1 mg/kg every day * Maximum 100 mg/dose | No | No |
| Tocilizumab  (TCZ) | Anti-IL-6 receptor antibody | IV | * weight <20 kg: 12 mg/kg every 2 weeks * weight >20 kg: 8 mg/kg every 2 weeks | Yes | Yes |
| Abatacept (ABA) | Modulator of T-cell  co-stimulation | IV | * 10 mg/kg, induction phase at 0, 2, 4 weeks, then every 4 weeks | Yes | Yes |
| Rituximab  (R) | Anti-CD20 antibody | IV | * Two doses of 750 mg/m2 at week 0 and 2 * Maximum 1000 mg/dose | No | No |

IV = intravenous, SC = subcutanous, TNF = tumour necrosis factor, IL = interleukin